232 related articles for article (PubMed ID: 27003552)
21. Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme.
Iveson T; Carter AM; Shiu KK; Spooner C; Stevens D; Mullamitha S
BMC Cancer; 2020 Feb; 20(1):91. PubMed ID: 32013902
[TBL] [Abstract][Full Text] [Related]
22. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.
Scheithauer W; McKendrick J; Begbie S; Borner M; Burns WI; Burris HA; Cassidy J; Jodrell D; Koralewski P; Levine EL; Marschner N; Maroun J; Garcia-Alfonso P; Tujakowski J; Van Hazel G; Wong A; Zaluski J; Twelves C;
Ann Oncol; 2003 Dec; 14(12):1735-43. PubMed ID: 14630678
[TBL] [Abstract][Full Text] [Related]
23. The value of oxaliplatin in combination with continuous infusion +/- bolus 5-fluorouracil and levo-folinic acid in metastatic colorectal cancer progressing after 5FU-based chemotherapy: a GISCAD (Italian Group for the Study of Digestive Tract) cancer phase II trial.
Mosconi S; Cascinu S; Zaniboni A; Catalano V; Giordani P; Beretta GD; Martignoni G; Pancera G; Baldelli AM; Poletti P; Curti C; Labianca R
Tumori; 2000; 86(6):465-9. PubMed ID: 11218187
[TBL] [Abstract][Full Text] [Related]
24. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
25. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.
Kumar A; Peixoto RD; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Speers CH; Cheung WY
Clin Colorectal Cancer; 2015 Dec; 14(4):262-8.e1. PubMed ID: 26123496
[TBL] [Abstract][Full Text] [Related]
26. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Van Cutsem E; Hoff PM; Harper P; Bukowski RM; Cunningham D; Dufour P; Graeven U; Lokich J; Madajewicz S; Maroun JA; Marshall JL; Mitchell EP; Perez-Manga G; Rougier P; Schmiegel W; Schoelmerich J; Sobrero A; Schilsky RL
Br J Cancer; 2004 Mar; 90(6):1190-7. PubMed ID: 15026800
[TBL] [Abstract][Full Text] [Related]
27. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.
Bendell JC; Bekaii-Saab TS; Cohn AL; Hurwitz HI; Kozloff M; Tezcan H; Roach N; Mun Y; Fish S; Flick ED; Dalal D; Grothey A
Oncologist; 2012; 17(12):1486-95. PubMed ID: 23015662
[TBL] [Abstract][Full Text] [Related]
28. Retrospective comparison of CAPOX and FOLFOX dose intensity, toxicity, and clinical outcomes in the treatment of metastatic colon cancer.
Loree JM; Mulder KE; Ghosh S; Spratlin JL
J Gastrointest Cancer; 2014 Jun; 45(2):154-60. PubMed ID: 24408272
[TBL] [Abstract][Full Text] [Related]
29. Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices.
Landsman-Blumberg PB; Carter GC; Johnson BH; Sedgley R; Nicol SJ; Li L; Shankaran V
Clin Colorectal Cancer; 2014 Sep; 13(3):178-84. PubMed ID: 25065655
[TBL] [Abstract][Full Text] [Related]
30. A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer.
Choi DR; Yoon SN; Kim HS; Kim JH; Kim KY; Kim BC; Choi YK; Kim JB; Han B; Song HH; Zang DY
Cancer Chemother Pharmacol; 2015 Mar; 75(3):639-43. PubMed ID: 25630415
[TBL] [Abstract][Full Text] [Related]
31. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Chun HK; Lee WY; Park YS
Med Oncol; 2010 Dec; 27(4):1277-85. PubMed ID: 19949897
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of Combining Bevacizumab With First-Line Chemotherapy Regimens for Metastatic Colorectal Cancer in Real-World Practice.
Bang YH; Hong YS; Lee JS; Lee KW; Han HS; Kim SY; Kim JW; Kim HK; Kim JW; Eun CK; Kim TW; Kim JE
Clin Colorectal Cancer; 2021 Jun; 20(2):101-112.e6. PubMed ID: 33223477
[TBL] [Abstract][Full Text] [Related]
33. A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer.
Zhi J; Chen E; Major P; Burns I; Robinson B; McKendrick J; Rittweger K; Abt M; Goldstein D
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1199-206. PubMed ID: 21409383
[TBL] [Abstract][Full Text] [Related]
34. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
[TBL] [Abstract][Full Text] [Related]
35. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
[TBL] [Abstract][Full Text] [Related]
36. Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401.
Comella P; Massidda B; Filippelli G; Farris A; Natale D; Barberis G; Maiorino L; Palmeri S; Cannone M; Condemi G;
J Cancer Res Clin Oncol; 2009 Feb; 135(2):217-26. PubMed ID: 18719941
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice.
Laterza MM; Pompella L; Petrillo A; Tirino G; Pappalardo A; Orditura M; Troiani T; Ciardiello F; Di Martino N; De Vita F
Med Oncol; 2017 Oct; 34(11):186. PubMed ID: 29043514
[TBL] [Abstract][Full Text] [Related]
38. Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.
Tran G; Hack SP; Kerr A; Stokes L; Gibbs P; Price T; Todd C
Asia Pac J Clin Oncol; 2013 Sep; 9(3):239-48. PubMed ID: 23279720
[TBL] [Abstract][Full Text] [Related]
39. [Difference analysis of chemotherapy efficacy among different primary tumor sites in metastatic colorectal cancer].
Sun Z; Wang X; Jia J; Liu C; Zhang X; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Oct; 19(10):1119-1123. PubMed ID: 27781247
[TBL] [Abstract][Full Text] [Related]
40. FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data.
Neugut AI; Lin A; Raab GT; Hillyer GC; Keller D; O'Neil DS; Accordino MK; Kiran RP; Wright J; Hershman DL
Clin Colorectal Cancer; 2019 Jun; 18(2):133-140. PubMed ID: 30878317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
